[Regression of diffuse large B-cell lymphoma after discontinuation of salazosulfapyridine]

Rinsho Ketsueki. 2022;63(2):99-103. doi: 10.11406/rinketsu.63.99.
[Article in Japanese]

Abstract

An 81-year-old man with a 3-year history of salazosulfapyridine (SASP) therapy for rheumatoid arthritis (RA) presented with pulmonary infiltrates and underwent computed tomography-guided biopsy. The histopathological and immunohistochemical evaluation confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). He was recommended chemotherapy, which he refused. Due to the possibility of other iatrogenic immunodeficiency-associated lymphoproliferative disorders, SASP therapy was discontinued. SASP therapy withdrawal led to near-complete resolution of the lung infiltration shadows, and the serum soluble interleukin 2 receptor level returned to the normal range. This is the first report of a case of remission of DLBCL, following SASP therapy withdrawal in a patient with RA.

Keywords: Diffuse large B-cell lymphoma; Other iatrogenic immunodeficiency-associated lymphoproliferative disorders; Rheumatoid arthritis; Salazosulfapyridine.

Publication types

  • Case Reports

MeSH terms

  • Arthritis, Rheumatoid* / complications
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / complications
  • Lymphoma, Large B-Cell, Diffuse* / diagnostic imaging
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoproliferative Disorders* / complications
  • Male
  • Sulfasalazine / therapeutic use

Substances

  • Sulfasalazine